Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - A case report

1Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Hepatitis C virus (HCV) infection is a recognised cause of secondary immune thrombocytopenia (ITP). While its incidence has been largely described during chronic HCV infection, only one case of ITP secondary to acute HCV infection has been reported at this time. Case presentation: We report herein the case of severe ITP secondary to an acute HCV genotype 1a reinfection in a human immunodeficiency virus (HIV)-negative man having sex with men who had been cured several years before of a previous acute genotype 4d HCV infection. After an unsuccessful standard therapy with two courses of intravenous immunoglobulin (at 1 g/kg daily for 2 days) associated with methylprednisolone 1 mg/kg daily, antiviral treatment with sofosbuvir-ledipasvir rapidly achieved virological response and normalised the platelet count. Conclusions: As a direct effect of HCV on megakaryocytes could be the predominant cause of ITP during acute infection, early antiviral treatment may be beneficial in this case.

Cite

CITATION STYLE

APA

Alcazer, V., Miailhes, P., Ramière, C., Charre, C., & Cotte, L. (2018). Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - A case report. BMC Infectious Diseases, 18(1). https://doi.org/10.1186/s12879-018-3597-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free